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Background: The aim of this study is to assess the factors inﬂuencing the early mortality (7-
day  after index blood culture) in haematological malignancy patients with Gram negative
bacilli  (GNB) bacteraemia.
Methods:  Infection control committee records were reviewed to identify the cases between
March  2006 and June 2011. Only one bacteraemic episode per patient was included in the
study.
Results:  A total of 154 patients with GNB bacteraemia were identiﬁed. The early mortal-
ity  rate was 19.5% (30 out of 154). Blood cultures revealed Enterobacteriacea in 120 patients
(Escherichia  coli; 86, Klebsiella spp.; 28, Enterobacter cloacea; 6) and glucose non-fermenting GNB
in  34 patients (Pseudomonas aeruginosa; 15, Acinetobacter baumannii; 11, Stenotrophomonas mal-
tophilia; 7, Burkholderia cepacia; 1). Forty (33.3%) out of 120 Enterobacteriaceae were extended
spectrum  beta-lactamase (ESBL) producers and 18 (52.9%) out of 34 glucose non-fermenting
GNB  were multidrug resistant. Carbapenems were administered as ﬁrst line therapy in 139
out of 154 patients. In univariate analysis Pitt’s bacteraemia score, presence of aplastic
anaemia,  bacteraemia caused by glucose non-fermentating GNB, inappropriate empiri-
cal  antibacterial treatment, presence of severe sepsis or septic shock, unable to achieve
microbiological  cure, and intensive care unit (ICU) acquired bacteraemia were associated
with  mortality. Multivariate analysis showed ICU acquired bacteraemia (OR, 12.55; 95% CI,
2.34–67.38, p = 0.003) as an independent factor associated with early mortality.
Conclusion: Haematological malignancy patients who require ICU care are at high risk for
early  mortality related to GNB bacteraemia. Based on the local ﬁndings pointing out highrate  of multidrug resistan
able  approach as empiric
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Introduction
The increasing incidence of Gram-negative bacilli infections
is  of concern in patients with haematological malignancies
or  undergoing stem cell transplantation. Treatment is chal-
lenging  due to the high rate of multidrug resistance.1 High
treatment costs and increased rate of mortality are well-
known  features of infections caused by multidrug resistant
Gram  negative bacilli (MDRGNB).2 However, the relationship
between antibacterial resistance and mortality is scarce. In
two  recent prospective observational studies, multidrug resis-
tance  (MDR) was  reported to be associated with mortality
in  haematological malignancy patients with Gram-negative
bacilli (GNB) bacteraemia, but the investigators were not able
to  show the impact of inappropriate empiric antibacterial
therapy on mortality.3,4 In our previous studies which evalu-
ated  the outcome of extended spectrum beta-lactamase (ESBL)
producing  Escherichia coli and MDR  Acinetobacter baumannii
bacteraemia in a group of patients with several immunocom-
promised conditions including haematological malignancies,
we  were  not able to show the impact of MDR  on mortality.5–7
However heterogeneity of the underlying diseases, presence
of  co-infections with several opportunistic pathogens, and
different  epidemiological characteristics of the centres could
have  inﬂuenced these ﬁndings.
The aim of this study is to assess the outcome of noso-
comial GNB bacteraemia in patients with haematological
malignancy or undergoing stem cell transplantation and ana-
lyze  the factors inﬂuencing mortality in our hospital.
Patients  and  methods
This study was  conducted at Erciyes University Hospital, a
1300-bed  tertiary care centre located in Kayseri, Turkey. The
records  of the infection control committee were retrospec-
tively  reviewed to identify the patients with monomicrobial
nosocomial GNB bacteraemia between March 2006 and June
2011.  Case patients were deﬁned as those who were >16 years
of  age, had at least one blood culture positive for GNB and
had  clinical signs of systemic infection.8 Only one bacteraemic
episode per patient was  included. This study was  approved by
the local ethics committee.
The  following demographic data were extracted from
patients’ charts: age, gender, hospital length of stay prior to
development  of bacteraemia, and intensive care unit (ICU)
stay,  underlying haematological malignancy, neutrophil count
at the day of blood culture, and receiving stem cell transplan-
tation.  The medical histories of the patients such as diabetes
mellitus  (DM), corticosteroid use, graft versus host disease,
acute  renal failure, chronic renal insufﬁciency requiring
haemodialysis, hepatic insufﬁciency, coronary artery disease,
congestive  heart failure and chronic obstructive lung dis-
ease  were  also recorded. Severity of illness was  calculated by
the  Pitt’s bacteraemia score9 and Charlson’s weighted index
10of  morbidity. Nosocomial bacteraemia and the sources of
bacteraemia were  deﬁned according to the criteria proposed
by  the Centers for Disease Control.11 Bacteraemia that was
detected  after 72 h of ICU care in patients who did not have 1 3;1 7(2):143–149
evidence  of bacteraemia at admission was characterized as
ICU  acquired.12 Severe sepsis was deﬁned as sepsis with one
or  more  signs of organ dysfunction. Septic shock due to GNB
bacteraemia was characterized by positive blood culture with
persistent  arterial hypotension (deﬁned as a systolic arterial
pressure  below 90 mmHg, mean arterial pressure <60 mmHg,
or  a reduction in systolic blood pressure of >40 mmHg  from
baseline)  unexplained by other causes and in spite of adequate
volume  rehydration.8
The initial empirical antimicrobial therapy was  considered
to  be “appropriate” if the initial antibiotics, which were  admin-
istered  within 24 h after collecting a blood sample for culture,
included  at least one antibiotic that was  active in vitro (except
ceftriaxone, cefotaxime and ceftazidime for ESBL producing
Enterobacteriaceae) and when the dosage and route of admin-
istration  were  in accordance with current medical standards.
Otherwise, the initial antimicrobial therapy was  considered as
“inappropriate”.5,7,13
During the study period, GNB isolated from blood cultures
were  identiﬁed by automated systems and antimicrobial sus-
ceptibility  and ESBL production were  tested according to Clini-
cal  Laboratory Standards Institute (CLSI) recommendations.14
Strains showing “intermediate” antimicrobial susceptibility
proﬁles were considered to be resistant. Colistin susceptibil-
ity  was determined by a disk diffusion test with 25 g colistin
(Oxoid,  UK), according to the British Society for Antimi-
crobial Chemotherapy (BSAC) criteria. The isolates with a
zone  diameter of ≥14 mm were accepted as susceptible.7
The strains of Pseudomonas aeruginosa and A. baumannii that
were  non-susceptible to ≥1 agent in ≥3 antimicrobial cate-
gories  were  deﬁned as multidrug resistant (MDR) based on the
recent  consensus report.15 Stenotrophomonas maltophilia that
is  intrinsically resistant to aminoglycosides and beta-lactam
antibiotics including carbapenems is also deﬁned as MDR.
Microbiological cure was deﬁned when the organism could not
be  isolated in repeat blood cultures during or after the course
of  therapy; failure was considered when cultures were  per-
sistently  positive for the same organism or development of a
superinfection with a microorganism other than initial GNB
at  least three days after treatment initiation.16,17
For statistical analysis, we divided the patients into two
groups  according to survival status 7-days after the ﬁrst
positive blood culture was obtained. All statistical analyses
were  performed with SPSS software for Windows (version
15.0;  SPSS, Chicago, IL). Continuous variables were expressed
as  median values, ﬁrst and third quartiles, categorical vari-
ables  were expressed as the frequencies and percentages of
the  patients analyzed. Groups were compared with use of
2 and Fisher’s exact tests for categorical variables, and the
Mann–Whitney U test for continuous variables. In order to
identify  the independent risk factors for mortality, univariate
and  multivariate logistic regression analysis were  used to con-
trol  for the effects of confounding variables. Odds ratios (ORs)
and  their 95% conﬁdential intervals (CIs) were  calculated. All
risk  factors with potential association with mortality (whether
they  were statistically signiﬁcant or not) and statistically sig-
niﬁcant  variables in univariate analysis were  included in the
multivariate  logistic model and backward stepwise selection
was  performed at a stringency level of p < 0.10 to determine the
independent  risk factors for 7-day mortality.4,18 Measures of
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he goodness-of-ﬁt were obtained to assess the performance
f  the models. All p-values were  two tailed, and p < 0.05 was
onsidered statistically signiﬁcant.
esults
 total of 154 patients with GNB bacteraemia were eligible for
he  study. Median age of the patients was  40.7 years (range;
6–76  years) and 86 were  male. The most common under-
ying  haematological malignancy was  acute myelogenous
eukaemia (AML). Twenty-ﬁve patients underwent allogenic
tem  cell transplantation (SCT) and 22 underwent autolo-
ous  SCT. The demographic characteristics of the patients are
hown in Table 1.
Of  the total, 120 patients had bacteraemia caused by
nterobacteriaceae (E. coli; 86, Klebsiella spp.; 28, Enterobacter
loacea; 6) and glucose non-fermenting GNB were isolated in
4  patients (P. aeruginosa; 15, A. baumannii; 11, S. maltophilia; 7,
urkholderia cepacia; 1). Forty (33.3%) out of 120 Enterobacteri-
ceae were  ESBL producers, and 18 (52.9%) out of 34 glucose
on-fermenting GNB were MDR. All MDR  strains of P. aerugin-
sa  and A. baumanni were resistant to cefepime, ciproﬂoxacin,
iperacillin/tazobactam, amikacin, and imipenem. Colistin
as  tested only against A. baumannii and all isolates were sus-
eptible.  Table 2 shows the antibacterial susceptibility proﬁle
f  the causative GNB isolated from blood cultures.
All but two patients received empirical antibiotic therapy
ithin an hour after the blood culture was performed. Car-
apenems  (imipenem, 105; meropenem, 32; doripenem, 2)
ere  the treatment of choice in 139 patients (27 of whom
ied),  ﬁve patients received piperacillin/tazobactam (one of
hom  died), two patients received cefoperazone/sulbactam
two of whom died), two patients received ciproﬂoxacin (none
f  them died), and two patients ceftriaxone (none of whom
ied).  One patient who  had an intrabdominal abscess received
igecycline  and another patient suffering from catheter infec-
ion  received teicoplanin as the empiric antibiotic therapy.
nappropriate empirical antibiotic therapy was  more  com-
on  in patients with poor outcome (43.3% vs 10.5%, p < 0.001).
ince  10 out of 11 A. baumannii strains and 4 out of 15 P.
eruginosa strains were  resistant to carbapenems, inappropri-
te  antibacterial therapy was  more  common in patients with
lucose  non-fermenting GNB bacteraemia. Although none of
he  patients with S. maltophilia bacteraemia received empiric
ntibiotic  therapy active against S. maltophilia only one patient
ied.  Severe sepsis or septic shock was  not detected in these
atients  and they did not receive ICU care. After the culture
esults  became available trimethoprim/sulfamethoxazole was
tarted  in three patients and ciproﬂoxacin was the treatment
hoice  in the other three patients with S. maltophilia bacter-
emia.
We  were  able to evaluate microbiological cure in 66 out of
6  patients with E. coli bacteraemia, 27 out of 28 patients with
lebsiella  spp. bacteraemia, 5 out of 6 patients with Enterobac-
er  cloacae bacteraemia, 11 out of 15 patients with P. aeruginosa
acteraemia, 8 out of 11 patients with A. baumannii bacter-
emia,  and 7 out of 7 patients with S. maltophilia and 1 out
f  1 Burkholderia cepacia bacteraemia. Microbiological cure was
ot  achieved in 15 out of 125 evaluable bacteraemic patients3;1  7(2):143–149  145
(ﬁve  with E. coli bacteraemia, three with Klebsiella pneumoniae
bacteremeia, two with E. cloacae bacteremeia, four with A. bau-
mannii  bacteremia). Microbiological cure rate was signiﬁcantly
higher  in surviving patients (81.5% vs 30.0%, p < 0.001) and
being  unable to achieve microbiological cure was associated
with  mortality (OR, 45.38; 95% CI, 10.34–199.14, p < 0.001) in the
univariate  analysis.
The  mortality rates at 7-day, and at 14-day of bacter-
aemia were 19.5%, and 26%, respectively. Seven out of 154
patients  died before culture results became available. Uni-
variate  analysis showed that high Pitt’s bacteraemia score
(OR,  1.79; 95% CI, 1.41–2.30, p < 0.001), presence of aplastic
anaemia (OR, 4.16; 95% CI, 1.32–13.11, p = 0.015) as the under-
lying  haematological disorder, bacteraemia caused by glucose
non-fermenting GNB (OR, 3.09; 95% CI, 1.30–7.33, p = 0.01),
inappropriate empirical antibacterial treatment (OR, 0.15; 95%
CI, 0.06–0.39, p < 0.001), presence of severe sepsis (OR, 12.75;
95%  CI, 5.03–32.35, p < 0.001) or septic shock (OR, 13.67; 95%
CI,  1.37–136.48, p = 0.026), and ICU acquired bacteraemia (OR,
10.91;  95% CI, 3.02–39.38, p < 0.001) were associated with mor-
tality.  Duration of hospitalization (OR, 1.02; 95% CI, 0.99–1.04,
p  = 0.17), ESBL production in Enterobacteriaceae (OR, 0.73;
95%  CI, 0.24–2.23, p = 0.59), MDR in glucose non-fermenting
GNB bacteraemia (OR, 4.33; 95% CI, 0.91–20.6, p = 0.07) and
severe  neutropenia (neutrophil count < 100 cells/mm3) (OR,
0.32;  95% CI, 0.02–4.51, p = 0.40) and neutropenia (neutrophil
count < 500 cells/mm3) (OR, 0.78; 95% CI, 0.02–25.4, p = 0.89)
were  not associated with mortality based on univariate anal-
ysis.
When  multivariate analysis was  performed to compare the
relative  contribution of risk factors associated with 7-day mor-
tality,  ICU acquired bacteraemia (OR, 12.55; 95% CI, 2.34–67.38,
p  = 0.003) was found to be independently associated early mor-
tality.  Of the 12 patients who were  receiving ICU care during
the  onset of bacteraemia, MDR  A. baumannii was  isolated in
three  patients, MDR P. aeruginosa in two patients and ESBL
producing E. coli was isolated in two patients. 11 out of 12
patients  had severe sepsis and septic shock was  diagnosed in
one patient. While 7 of the patients with Enterobacteriaceae
(E. coli; 4, Klebsiella spp.; 2, E. cloacea; 1) bacteraemia received
appropriate antibiotic therapy, none of the patients with A.
baumannii  or P. aeruginosa bacteraemia received appropriate
antibacterial therapy.
Discussion
Patients with haematological malignancies or receiving stem
cell  transplantation are highly vulnerable to serious infec-
tious.  Deﬁning the causes of the attributable mortality is
difﬁcult  in this group of patients. Several studies used 14 or
30-day  mortality as the main outcome measure in haemato-
logical  malignancy patients with GNB. However,  this a very
long  time to detect the relationship between mortality and
bacteremia,  because patients with haematological malignan-
cies  have several cofounders for mortality particularly in a
3,4,19,20follow  up period of 14 or 30 days. So, we  decided to use
7-day  survival as the main outcome measure in this study.
In  this retrospective observational study the early mortal-
ity  rate (7-days after index blood culture) was  19.5% among
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Table 1 – Baseline demographic and clinical characteristics of the haematological malignancy patients with Gram
negative bacilli bacteraemia.
Characteristics Total n = 154 Non-survived n = 30 (%) Survived n = 124 (%) p valuea
Age, median (range), years 40.7 (16–76) 47.5 (16–76) 40.0 (16–76) 0.31
Gender 0.76
Male 86 (55.8) 18 (60.0) 68 (54.8)
Female 68 (44.2) 12 (40.0) 56 (45.2)
Haematological diagnosis 0.02
Leukaemias 92 (59.7) 16 (53.3) 76 (61.3)
Acute mylogenous leukaemia 63 (40.9) 13 (43.3) 50 (40.3)
Acute lymphocytic leukaemia 26 (16.9) 3 (10.0) 23 (18.5)
Chronic lymphocytic leukaemia 3 (1.9) 0 3 (2.4)
Lymphoma 30 (19.5)  3 (10.0) 27 (21.8)
Hodgkin lymphoma 13  (8.4) 2 (6.7) 11 (8.9)
Non-Hodgkin lymphoma 17 (11.0) 1 (3.3) 16 (12.9)
Multiple myeloma 17 (11.0) 4 (13.3) 13 (10.5)
Aplastic anaemia 15 (9.7) 7 (23.3) 8 (6.5)
Hematopoietic stem cell transplantation 47 (30.5) 5 (16.7) 42 (33.9) 0.1
Allogenic 25 (16.2) 5 (16.2) 20 (16.1)
Autologous 22 (14.3) 0 (0.0) 22 (17.7)
Comorbid diseases 15 (6.7) 5 (16.6) 10 (8.0) 0.17
Acute renal failure 10 (15.4) 4 (1.9) 6 (4.8)
Graft versus host disease 3 (1.9) 0 (0.0) 3 (2.4)
Diabetes mellitus 1 (0.6) 1 (3.3) 0
Goodpasture syndrome 1 (0.6) 0 (0.0) 1 (0.8)
Source of bacteremia 0.13
Primary bacteremia 111(72.1) 23 (76.7) 88 (71.0)
Catheter related 27 (17.5)  2 (6.7) 25 (20.2)
Other 16 (10.3) 5 (16.6) 11 (8.8)
Pneumonia 5 (3.2) 4 (13.3) 1 (0.8)
Urinary tract infection 6 (3.9) 1 (3.3) 5 (4.0)
Abscess 5 0 (0.0) 5 (4.0)
Duration from admission to bacteremia median
(days) (range)
22.7  (1–92) 17.0 (1–92) 24.0 (1–55) 0.03
Corticosteroid use 16 (10.4) 5 (16.7) 11 (8.9) 0.31
Neutrophil counts 0.29
<100 cells/mm3 123(79.9) 27 (90.0) 96 (77.4)
100–500 cells/mm3 13 (8.4) 1 (3.3) 12 (9.7)
>500 cells/mm3 18 (11.7) 2 (6.7) 16 (12.9)
Pitt’s bacteremia score, median (range) 1.27 (0–8) 2.5 (0–8) 0 (0–6) <0.001
Charlson comorbidity index, median (range) 2.17 (0–6) 2.0 (0–4) 2.0 (0–6) 0.3
Severe sepsis 44 (28.6) 22 (73.3) 22 (17.7) <0.001
Septic shock 4 (2.6) 3 (10.0) 1 (0.8) 0.024
Enterobacteriaceae 120 (77.9) 18 (60.0) 102 (82.3) 0.017
Esherichia coli 86 10 76
Klebsiella pneumoniae 25 5 20
Klebsiella spp. 3 0 3
Enterobacter cloacea 6 3 3
Glucose non-fermenting Gram negative bacilli 34 (22.1) 12 (40.0) 22 (17.7)
Pseudomonas aeruginosa 15 3 12
Acinetobacter baumannii 11 8  3
Stenotrophomonas maltophilia 7 1 6
Burkholderia cepacia 1 0 1
Multidrug resistant non-fermenter Gram
negative bacilli (n:34)
18  (52.9) 9 (75.0) 9 (40.9) 0.12
ESBL producing Enterobacteriaceae (n:120) 40 (33.3) 5 (27.8) 35 (34.3) 0.78
Intensive care unit acquired bacteraemia 12 (7.8) 8 (26.7) 4 (3.2) <0.001
Inappropriate empiric antibiotic treatment 26 (16.9) 13 (43.3) 13 (10.5) <0.001
ESBL, extended spectrum beta-lactamase.
Values  are expressed as n (%) or median (25th and 75th percentiles).
a p Value for 2, Fisher’s exact, and Mann–Whitney U test, were applicable.
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Table 2 – Antibacterial susceptibility rates of the causative Gram negative bacilli isolated from blood cultures.
Microorganisms IMP, % SAM, % TZP, % CTX, % CAZ, % CFP, % CIP, % AN, % NN, % SXT, %
Escherichia coli (n = 86) 100 46.2 78.3 65.1 NA NA 25.0 93.5 92.8 23.8
Klebsiella spp. (n = 28) 100 40.7 75.0 71.4 NA NA 75.0 95.8 92.3 41.2
Pseudomonas aeruginosa (n = 15) 73.3 NA 86.7 NA 86.6 85.7 86.6 92.8 100 NA
Acinetobacter baumannii (n = 11) 9.1 20 18.2 0 0 0 9.1 22.2 85.7 11.1
Stenotrophomonas maltophilia (n = 7) NA NA NA NA 42.8 NA 85.7 NA NA 100
Enterobacter cloacae (n = 6) 100 16.6 50.0 83.3 NA NA 50.0 100 NA 16.6















































dIMP, imipenem; SAM, ampicillin/sulbactam; TZP, piperacillin/tazobac
AN, amikacin; NN, netilmicin; SXT, trimethoprim/sulfamethoxazole;
aematological malignancy patients with GNB bacteraemia.
he  early mortality rate was  found to be 18% in 51 can-
er  patients with MDRGNB bacteraemia which was not
tatistically different when compared to 312 patients with
on-MDRGNB bacteraemia.4 Based on the ﬁndings of the same
tudy  group, early mortality and overall mortality (30-days
fter  the index blood culture) were similar in cancer patients
ith  ESBL producing E. coli and non-ESBL producing E. coli
acteraemia.19 Although inappropriate antimicrobial therapy
as  signiﬁcantly more  common in patients with poor out-
ome,  we  were  not able to show signiﬁcance of this ﬁnding in
ultivariate  analysis. This is concordant with the recent stud-
es  evaluating the outcome of bacteraemia in patients with
aematological malignancies.4,19–21 However, not being able
o  adjust for differences between treatment groups receiv-
ng  appropriate or inappropriate antibacterial therapy using
ultivariate techniques commonly used may  have been the
eason  for this ﬁnding.13
Our ﬁndings showed ICU acquired bacteraemia as the only
igniﬁcant  factor associated with mortality in the multivari-
te  analysis. The prognosis of patients with haematological
alignancies who are admitted to the ICU is generally poor
nd  culture proven infection was  reported to be related with
oor  outcome.22,23 A recent study showed that GNB bac-
eraemia approximately doubled the risk of death in ICU
atients.12 Carbapenems should be the ﬁrst choice in an
ndemic  area of ESBL producing Enterobacteriaceae and addi-
ion  of colistin in the empirical regimen can improve the
utcome  in the setting of MDR  A. baumannii and P. aerugin-
sa.  Although using carbapenems as ﬁrst line therapy in the
reatment  of febrile neutropenic patients seems to be a rea-
onable  approach when ESBL producing Enterobacteriaceae
s common, the potential of triggering infections caused by
arbapenem  resistant glucose non-fermenting GNB is of con-
ern.  In a retrospective analysis of antimicrobial resistance
n  our intensive care units carbapenem resistance in A. bau-
annii  doubled at the end of ten years.24 De-escalation of
arbapenems is an important strategy after blood culture
esults  become available to avoid unnecessary use of broad
pectrum  antibiotics.
Aside  from the statistical analysis the percentage of ESBL
roducing Enterobacteriaceae as high as 33.3% was sig-
iﬁcant.  Fluoroquinolones have been widely used in our
ospital  in patients undergoing stem cell transplantation
nd receiving high dose chemotherapy for AML. Exposure to
uoroquinolone was  reported to be associated with ESBL pro-
uction  in E. coli and K. pneumoniae as well as carbapenemCTX, cefotaxime; CAZ, ceftazidime; CFP, cefepime; CIP, ciproﬂoxacin;
ot available.
resistance in A. baumannii.25–27 Previous studies from our hos-
pital  and several hospitals around the country showed a high
rate  of cefepime resistance or ESBL production in E. coli and
K.  pneumoniae.21,28–30 Such consequences led carbapenems to
become  ﬁrst line therapy particularly in the treatment of
febrile  neutropenia in our hospital. However, the heavy use
of  carbapenems resulted in the emergence of a high rate of
carbapenem  resistant A. baumannii and S. maltophilia bacter-
aemia.  When we  checked the medical records of these patients
we  witnessed the use of carbapenems in the treatment of
febrile  neutropenia for several episodes. Due to the retro-
spective nature of study we could not test the clonality of
isolates,  but the patients were hospitalized at different time
periods  which excluded cross-transmission between patients.
Although  we did not experience any carbapenem resistance
in  Enterobacteriaceae, the ﬁrst isolate of carbapenem resis-
tant  E. coli from Turkey was reported from a hospital with
heavy  use of carbapenems in treatment of ESBL produc-
ing  E. coli bacteraemia.31 A previous study from our hospital
showed that piperacillin/tazobactam resistance was  44.7% in
E. coli, 34.4% in K. pneumoniae, and 27.7% in P. aeruginosa iso-
lated  from febrile neutropenic patients.28 After discontinuing
piperacillin/tazobactam as ﬁrst line therapy particularly in
febrile  neutropenic patients with long duration of hospital-
ization, currently the susceptibility to piperacillin/tazobactam
is between 75 and 86.7% (Table 2). A recent post hoc anal-
ysis  showed the efﬁcacy of piperacillin/tazobactam in the
treatment  of ESBL producing E. coli.32 Piperacillin/tazobactam
monotherapy or in combination with amikacin seems to be a
reasonable alternative for treating febrile neutropenia in our
hospital  to reduce carbapenem use particularly in patients
with  stable clinical condition. Such kind of policy evalu-
ations could help all centres to avoid heavy carbapenem
usage. Some institutions have some concerns about the use
of  piperacillin/tazobactam in the treatment of febrile neu-
tropenia  due to cross-reaction of the antibiotic with serum
galactomanan antigenemia which is an important marker for
early diagnosis of invasive aspergillosis. There are conﬂicting
results  about this interaction even studies from the same
country  in the same time interval.33,34 However,  there are at
least  two recent studies that showed no interaction between
piperacillin/tazobactam and galactomannan antigen when
original  brand is used.35,36Despite the efforts to implement infection control pro-
grammes MDRGNB infections seem to be an important
problem for healthcare settings. Colistin is an alternative for
the  treatment of MDR P. aeruginosa and A. baumannii infections.
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Clinical cure was  achieved in 20 out of 26 haematological
malignancy patients with MDR  P. aeruginosa infections of
whom  69% had bacteraemia.37 Tigecycline has been consid-
ered  as an alternative for MDR  A. baumannii infections based
on  in vitro high susceptibility rates. Previously, we reported
favourable outcome of carbapenem resistant A. baumannii
wound infection in an AML  patient treated with tigecyline.17
However the serum concentration of tigecycline is low at
standard  dosing which warrants special consideration when
using  tigecycline in the treatment of bloodstream infections.38
Our study has some limitations. This a retrospective study
from  a single centre analysing heterogenous groups of GNB
bacteraemia which do not share the same epidemiological and
clinical  characteristics. In addition, the types of haematologi-
cal  malignancies or stem cell transplantation were different
which  makes it difﬁcult to generalize the ﬁndings for all
patient  groups. Additionally, using the infection control com-
mittee  records to identify the cases could have missed the
patients  with bacteraemia at admission.
As a conclusion, the ﬁndings of this study did not prove the
role  of inappropriate empirical antimicrobial therapy in early
mortality  among patients with haematological malignancy or
undergoing SCT. However, it is apparent that the initial empiric
therapy  in most cases (139 out of 154) included carbapenems
and  then, of course, it would have been difﬁcult to single
out  inappropriate therapy as a risk factor, since carbapen-
ems  were  appropriate treatment for most cases. ICU acquired
bacteraemia was  the only statistically signiﬁcant risk factor
for  mortality. Special attention should be paid for the ini-
tial  antibiotic therapy of haematological malignancy patients
receiving  ICU care or with severe sepsis with multiorgan fail-
ure.  Since new antimicrobial regimens for MDRGNB is far away,
institutional  policies including the judicious use of antibacte-
rials  based on the local surveillance data and implementing
infection control measures to avoid the spread of resistant
microorganisms are essential.
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